510(k) K213348
K213348 is an FDA 510(k) premarket notification submitted by Leica Biosystems Newcastle, Ltd. for the device "BOND MMR Antibody Panel". The FDA issued a decision of Substantially Equivalent on Feb 21, 2023. The device falls under product code PZJ (Lynch Syndrome Test System), a Class II device regulated under 21 CFR 864.1866. Leica Biosystems Newcastle, Ltd. has 2 other 510(k) clearances on record.
Clearance details
- Decision
- SESE (Substantially Equivalent)
- Decision Date
- Feb 21, 2023
- Date Received
- Oct 8, 2021
- Clearance Type
- Traditional
- Expedited Review
- No
- Third Party Review
- No
Device classification
- Device Name
- Lynch Syndrome Test System
- Device Class
- Class II
- Regulation Number
- 864.1866
- Review Panel
- PA
- Submission Type
- 510(k)
The Lynch syndrome test system is used to identify loss of DNA mismatch repair proteins or microsatellite instability in tumor tissue from cancer patients for the purpose of identifying patients who may benefit from additional testing for the inherited cancer predisposition Lynch Syndrome
Need the full FDA record for Leica Biosystems Newcastle, Ltd.? Ask Claude or ChatGPT with the RegDataLab connector and get every site's inspections, Form 483s, warning letters, recalls and import alerts, each with a link to the FDA source. The API key is free: no card.